Bavarian Nordic stock zooms ~62% on smallpox vaccine Imvanex deal in Europe to fight monkeypox

May 19, 2022 1:32 PM ETBavarian Nordic A/S (BVNRY), BVNKFBy: Ravikash, SA News Editor4 Comments

Monkeypox title background

blackdovfx/iStock via Getty Images

  • Bavarian Nordic (OTCPK:BVNKF) (OTCPK:BVNRY) said it secured a contract with an undisclosed European country to supply its Imvanex smallpox vaccine in response to new cases of monkeypox in May.
  • The Denmark-based company's stock rose ~62% to $30.48 on May 19 in US trading. Meanwhile, the shares closed +29.46% to DKK183 May 19 on the Copenhagen Stock Exchange where it trades under the ticker BAVA.
  • While the first European case was confirmed on May 7, more than 20 cases have been confirmed in England, Portugal and Spain, said the company in a May 19 press release.
  • Bavarian said its smallpox vaccine is approved in the U.S. as Jynneos and in Canada as Imvamune. In both countries the approval extends to cover the monkeypox indication.
  • The company added that Imvanex is approved in Europe for smallpox but has previously been provided for off-label use in response to monkeypox cases.
  • The order has no impact on Bavarian's guidance for 2022, said the company.

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.